Business Context and Reporting Period
Company: Amneal Pharmaceuticals, Inc. (AMRX)
Filing Type: Form 8-K (Current Report)
Date of Report: December 10, 2019
Event: Entry into a Material Definitive Agreement to acquire a majority interest in AvKARE Inc. and R&S Northeast LLC.
Key Financial Metrics and Transaction Structure
This filing details a specific acquisition transaction rather than periodic financial performance. Key financial terms include:
- Implied Enterprise Value: $340 million.
- Acquisition Stake: Approximately 65% of the Target entities.
- Cash Consideration: $255 million payable at or in connection with closing.
- Debt Financing (Facilities): $210 million in first lien senior secured credit facilities (not guaranteed by Amneal).
- Term Loan: $180 million.
- Revolving Credit Facility: $30 million.
- Equity Contribution: $76 million committed by the Company.
- Seller Notes: Approximately $44.2 million in long-term promissory notes issued to sellers.
- Balance: Remaining enterprise value contributed via selling shareholders' rollover interest.
Note: The filing does not provide Amneal's current revenue, profit, cash flow, or liquidity metrics.
Material Changes and Transaction Details
The primary material change is the agreement to acquire two entities:
- AvKARE Inc.: A major private label provider of generic pharmaceuticals in the U.S. federal agency sector (Department of Defense and Department of Veterans Affairs).
- R&S Northeast LLC: A national pharmaceutical wholesaler focused on 340b-qualified entities.
Exclusions: The acquisition excludes AvKARE's business involving medical surgical supplies, laboratory consumables, durable medical equipment, and other non-pharmaceutical items, which will be disposed of prior to closing.
Outlook, Risks, and Contingencies
Use of Proceeds: Funds from the equity commitment and credit facilities will finance the acquisition consideration, refinance/repay existing Target indebtedness, and pay transaction fees.
Future Opportunity: Sellers granted Rondo an exclusive 180-day right post-closing to negotiate the purchase of Apace Packaging LLC, a pharmaceutical packaging solutions provider.
Termination Risks: The agreement may be terminated if:
- There is a material breach of representations or covenants.
- Closing does not occur by June 30, 2020 (subject to extension).
- Governmental authorities prohibit the transaction or issue a final restraining order.
Legal Disclaimer: Representations and warranties in the agreement are for the benefit of the parties only and may not reflect the actual state of facts for investors.
Investor Verification Checklist
- Verify the final closing date and whether the June 30, 2020 deadline was met or extended.
- Confirm the successful execution of the $210 million credit facilities and the $76 million equity contribution.
- Monitor the disposal of AvKARE's non-pharmaceutical assets prior to closing.
- Assess the outcome of the exclusive negotiation period for the potential acquisition of Apace Packaging LLC.
- Review subsequent filings for any material changes to the $340 million enterprise value or deal structure.